Brokerages expect Pacific Biosciences (NASDAQ:PACB) to post ($0.19) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Pacific Biosciences’ earnings. The lowest EPS estimate is ($0.19) and the highest is ($0.18). Pacific Biosciences reported earnings of ($0.26) per share in the same quarter last year, which would suggest a positive year over year growth rate of 26.9%. The business is scheduled to announce its next earnings results on Wednesday, April 25th.
On average, analysts expect that Pacific Biosciences will report full-year earnings of ($0.63) per share for the current fiscal year, with EPS estimates ranging from ($0.68) to ($0.58). For the next fiscal year, analysts expect that the company will report earnings of ($0.48) per share, with EPS estimates ranging from ($0.65) to ($0.36). Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Pacific Biosciences.
Pacific Biosciences (NASDAQ:PACB) last issued its earnings results on Thursday, February 1st. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.02. Pacific Biosciences had a negative net margin of 98.63% and a negative return on equity of 98.98%. The company had revenue of $24.94 million during the quarter, compared to analysts’ expectations of $21.89 million. During the same period last year, the company posted ($0.21) earnings per share. The firm’s quarterly revenue was down 3.1% compared to the same quarter last year.
Pacific Biosciences stock traded down $0.13 during mid-day trading on Monday, reaching $2.05. The company had a trading volume of 1,826,553 shares, compared to its average volume of 1,053,430. Pacific Biosciences has a 1 year low of $2.03 and a 1 year high of $5.70. The company has a current ratio of 3.55, a quick ratio of 2.74 and a debt-to-equity ratio of 0.16. The stock has a market cap of $267.92, a PE ratio of -2.36 and a beta of 1.54.
Institutional investors have recently modified their holdings of the business. Moloney Securities Asset Management LLC purchased a new position in Pacific Biosciences in the fourth quarter valued at about $154,000. Aperio Group LLC grew its position in shares of Pacific Biosciences by 105.5% in the third quarter. Aperio Group LLC now owns 42,396 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 21,766 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Pacific Biosciences by 7.9% in the second quarter. The Manufacturers Life Insurance Company now owns 70,533 shares of the biotechnology company’s stock valued at $250,000 after purchasing an additional 5,145 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Pacific Biosciences in the fourth quarter valued at approximately $301,000. Finally, Two Sigma Investments LP acquired a new stake in shares of Pacific Biosciences in the fourth quarter valued at approximately $370,000. 59.46% of the stock is owned by institutional investors.
Pacific Biosciences Company Profile
Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pacific Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.